The Medical Foods for Inborn Errors of Metabolism Market Size was estimated to be US$ 2.98 billion in 2021 and US$ XX billion in 2023 and is expected to reach US$ 9.76 billion by 2031; it is estimated to record a CAGR of 13.4% in till 2031. Growing online distribution platforms are likely to remain key Medical Foods for Inborn Errors of Metabolism Market Trends.
Inborn errors of metabolism refer to inherited disorders that are a result of mutations in genes coding for proteins functioning in metabolism. The inborn errors of metabolism are a heterogeneous group of disorders and are likely to be inherited through spontaneous mutation. The diseases usually involve failure of metabolic pathways that are either involved in breakdown or storage of biomolecules such as carbohydrates, proteins, and fatty acids. According to the National Center for Biotechnology Information (NCBI) in July 2023, inborn errors occur in 1 among 2,500 births making them significantly common across the world. A few commonly occurring inborn errors of metabolism include phenylketonuria (PKU), maple syrup urine disease, galactosemia, and fructose intolerance. Medical foods for inborn errors of metabolism act as nutritional treatment for patients with limited or compromised capacity to ingest, digest, absorb, or metabolize ordinary foods or nutrients. Thus, the increasing incidence of these diseases worldwide is expected to augment the demand for medical foods for inborn errors of metabolism, thereby supporting the market growth.
North America is the largest market for medical foods for inborn errors of metabolism market, with the US holding the largest market share, followed by Canada. The growth of the market in the US is driven by factors such as, the rising prevalence of inborn errors of metabolism, increasing newborn screening, and availability of a wide range of medical food for varied metabolic errors. Similarly, in Canada, increasing government initiatives to raise awareness regarding rare genetic disorders and well-established healthcare infrastructure are leading to market growth.
Australian Government launched The Inborn Errors of Metabolism (IEM) program, which helps people and families who have problems breaking down protein in their food. They need a special diet, and the IEM program helps them pay for their specialized food. This initiative is important because people with an IEM need low-protein, high-fat, and phenylalanine-free diets. These foods are very expensive. The money is used to buy these foods, so they stay on their diets and stay healthy. Thus, growing such initiatives by governments to create awareness about inborn errors of metabolism is a major driver of global inborn errors of metabolism market share.
The healthcare industry has been witnessing rapid transformations during the previous years. Countries across the globe have preferred advanced solutions that are simple to use and effective in healthcare. With a need for better healthcare facilities, technology-enabled care (TEC) solutions are being preferred in the healthcare systems in emerging economies. Increase in the aging population, incidences of chronic illnesses, and lack of pediatric care, as well as genetic disorders, are likely to be the primary factors driving the growth of the healthcare industry.
Various established players in the industry have been investing significant amounts of their revenue in R&D activities for the development of better and advanced solutions to cater the increasing needs of their customers. Also, the availability of reimbursement for various medical foods increasing these days is expected to fuel the growth of the industry in the coming years. With regulations laid down by the government bodies, it is possible to obtain better and reliable health management solutions, ensuring quality care, patient safety, and disease management. For instance, In July 2023, The Food and Drug Administration (FDA) has released a revised draft guidance for the industry on optimizing and standardizing diet in clinical trials for drug product development. The guidance is titled "Inborn Errors of Metabolism That Use Dietary Management: Considerations for Optimising and Standardizing Diet in Clinical Trials for Drug Product Development." This guidance sets out the FDA's current recommendations for developing drug products that treat inborn errors of metabolism (IEM) where dietary management is a crucial part of patients' metabolic control. The FDA believes that optimizing and standardizing dietary management in these patients before and during clinical trials is vital to ensure an accurate evaluation of the efficacy of new drug products. The increasing focus towards preventive health and adoption of easy treatment options such as medical foods and nutritional supplements for the management of various metabolism associated diseases acquired during the birth are likely to offer opportunistic scenario for the growth of the market over coming years.
Key segments that contributed to the derivation of the medical foods for inborn errors of metabolism market analysis are product, age group, disease, form, packaging, distribution channel.
The geographic scope of the medical foods for inborn errors of metabolism market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South America/South & Central America.
North America has dominated the medical foods for inborn errors of metabolism market. The market for medical foods for inborn errors of metabolism (IEMs) in the US holds the largest share among the countries of North America. Several government bodies in the country are engaged in establishing comprehensive guidelines for the management of IEMs. For instnace, in December 2023, the FDA announced the creation of a new advisory committee that will focus on potential treatments for genetic metabolic diseases. The committee, called the Genetic Metabolic Diseases Advisory Committee, will offer independent and knowledgeable advice and recommendations to the FDA on technical, scientific, and policy issues pertaining to medical products for genetic metabolic diseases. The members of the committee will evaluate evidence related to the applications brought before them and provide their recommendations for FDA consideration. The committee will comprise experts in the areas of management of inborn errors of metabolism, metabolic genetics, small population trial design, epidemiology, statistics, translational science, pediatrics, and other related specialties. Asia Pacific is anticipated to grow with the highest CAGR in the coming years.
The regional trends and factors influencing the Medical Foods for Inborn Errors of Metabolism Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Medical Foods for Inborn Errors of Metabolism Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 2.98 Billion |
| Market Size by 2031 | US$ 9.76 Billion |
| Global CAGR (2023 - 2031) | 13.4% |
| Historical Data | 2021-2023 |
| Forecast period | 2023-2031 |
| Segments Covered |
By Product
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The Medical Foods for Inborn Errors of Metabolism Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Medical Foods for Inborn Errors of Metabolism Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The medical foods for inborn errors of metabolism market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for medical foods for inborn errors of metabolism:
The “Medical Foods for Inborn Errors of Metabolism Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas: